Company will participate in three events at the largest global translation-focused cell and gene therapy meeting

ANN ARBOR, Mich.– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”) announces that the Company’s Board of Directors held its first meeting with its four new members-elect in attendance. During this meeting, management briefed the board on the Company’s plans for 2020 expansion and growth. The scheduled increases in spider silk production for 2020 and the role of the new “knock-in/knock-out” technology were also discussed.

Amgen’s KRAS inhibitor has shown limited efficacy in early testing in patients with cancers outside of the lung. The study linked the high dose of AMG-510 to a response rate of 12% in colorectal cancer patients and found similar efficacy in other solid tumor types.

An international team led by scientists at Aston University in the United Kingdom may have found a new use for the old antipsychotic trifluoperazine, a conventional schizophrenia treatment.

Gossamer Bio revealed this week that its chief medical officer, Jakob Dupont, M.D., would be departing to “pursue oncology opportunities closer to his family.” Two days later, we know where he’s landed: Atara Biotherapeutics, a South San Francisco biotech working on off-the-shelf T-cell therapies.

Legend Biotech is hoping it can ride the biotech IPO wave and take in a cool $100 million for its cell therapy work.

One year after its ASCO debut, Blueprint Medicines’ RET inhibitor continues to deliver. Echoing results presented last year from just 35 evaluable patients, pralsetinib shrank tumors in 61% of a difficult-to-treat group of lung cancer patients and curbed tumor growth in 95% of them.

Targeted therapies and checkpoint inhibitors have transformed melanoma treatment, but Novartis thinks combining the two could work even better.

Sunovion Pharma is calling it quits on dasotraline, a dopamine and norepinephrine reuptake inhibitor it was developing for binge eating disorder and attention deficit hyperactivity disorder (ADHD). It withdrew New Drug Applications for both indications and stopped development of the program.

Avrobio has provided interim data from a phase 2 trial of its Fabry disease gene therapy AVR-RD-01. The update shows the positive effects on biomarkers seen early in the trial have now persisted for up to 22 months, leading Avrobio to talk up the durability of its one-time treatment.